Ken Griffin Jan One Inc. Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$2.5 - $4.25 $35,255 - $59,933	-14,102 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$3.86 - $6.65 $54,433 - $93,778	14,102 New	14,102 $57,000
Q3 2021 Nov 15, 2021	SELL	$5.98 - $8.0 $101,845 - $136,248	-17,031 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$5.9 - $9.46 $88,134 - $141,313	-14,938 Reduced 46.73%	17,031 $132,000
Q1 2021 May 17, 2021	BUY	$4.47 - $12.99 $35,514 - $103,205	7,945 Added 33.07%	31,969 $269,000

Q4 2020 Feb 16, 2021	BUY	$3.5 - $5.44 $84,084 - $130,690	24,024 New	24,024 $117,000

165K

Ticker JAN
Exchange NASDAQ
Sector Industrials
Industry Waste Management
Shares Outstandng 3,150,230
Market Cap $7.06M
Description
JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through three segments: Biotechnology, Recycling, and Technology. ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.